Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president
Management at Varian Medical Systems Oncology Systems business unit has been restructured to consolidate global operations and provide additional management resources for developing early-stage emerging businesses, according to company CEO and president Richard M. Levy. Tim Guertin is the company's new executive vice president. Guertin will continue as president of Varian's Oncology Systems business in addition to assisting Levy with corporate issues. Several other new appointments were made within Oncology Systems.
John Ford, corporate vice president, has been named senior vice president for Oncology Systems, responsible for facilitating major customer, government, and partnering initiatives. Jeff Marcus, vice president of Oncology Systems, will assume responsibility for the worldwide sales organization. Paul Rowland, vice president of North American sales, Oncology Systems, will head the sales organization in the U.S. and Canada. He will report to Marcus. The medical manufacturing operations for Oncology Systems will be combined under Keith Krugman, corporate vice president and vice president, Oncology Systems, who will have continuing responsibility for worldwide customer support functions. Elaine McKinley has been appointed vice president, Oncology Systems customer support, reporting to Krugman. Product engineering and marketing have been combined under the direction of Kolleen Kennedy, vice president, Oncology Systems. Ueli Graf, vice president, worldwide engineering, Oncology Systems, will report to Kennedy.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.